Commentary

TikTok’s fave weight loss drugs: Link to thyroid cancer?


 

How to advise our patients and respond to the EMR messages

The TikTok videos may continue, the celebrity chatter may increase, and we, as physicians, will continue to look to real-world data with randomized controlled trials to tailor our decision-making and guide our patients.

It’s prudent to advise patients that if they have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, in particular, they should avoid using this class of medication. Thyroid cancer remains a rare outcome, and GLP-1 receptor agonists remain a very important and beneficial treatment option for the right patient.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Burden of thyroid cancer: Substantial and increasing
MDedge Hematology and Oncology
No link between cell phones and brain tumors in large U.K. study
MDedge Hematology and Oncology
Thyroid autoimmunity linked to cancer, but screening not advised
MDedge Hematology and Oncology
Children with low-risk thyroid cancer can skip radioactive iodine
MDedge Hematology and Oncology
Safe to expand limits of active surveillance in thyroid cancer?
MDedge Hematology and Oncology
New EU guidelines: Individualize care for thyroid cancer in kids
MDedge Hematology and Oncology
USPSTF holds firm on postmenopausal hormone recommendations
MDedge Hematology and Oncology
Lifestyle choices could curb genetic risk for thyroid cancer
MDedge Hematology and Oncology
Commenting on weight’s not rude. It’s dangerous.
MDedge Hematology and Oncology
Taking a break from TKIs unlikely to shorten survival
MDedge Hematology and Oncology